CAR Macrophage Immunotherapy
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
54
NCT04660929
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: Feb 2, 2021
Completion: Dec 31, 2024
NCT06254807
CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors
Start: Jan 8, 2024
Completion: Mar 31, 2026
Loading map...